MyoKardia, Inc. (MYOK)
(Delayed Data from NSDQ)
$49.32 USD
+1.92 (4.05%)
Updated May 3, 2019 04:00 PM ET
After-Market: $49.29 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$49.32 USD
+1.92 (4.05%)
Updated May 3, 2019 04:00 PM ET
After-Market: $49.29 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Should You Invest in the SPDR SP Pharmaceuticals ETF (XPH)?
by Zacks Equity Research
Sector ETF report for XPH
Bristol-Myers (BMY) Q3 Earnings Beat, '20 EPS View Raised
by Zacks Equity Research
Bristol-Myers (BMY) beats on earnings and sales in the third quarter on strength of Revlimid and Eliquis.
Qorvo, Nikola, BMY, MyoKardia and Geron as Zacks Bull and Bear of the Day
by Zacks Equity Research
Qorvo, Nikola, BMY, MyoKardia and Geron as Zacks Bull and Bear of the Day
Is a Beat in the Cards for Bristol-Myers' (BMY) Q3 Earnings?
by Zacks Equity Research
Investors will focus on regular top and bottom-line numbers along with key pipeline updates when Bristol-Myers (BMY) reports third-quarter 2020 results.
M&A ETF (MNA) Hits New 52-Week High
by Sweta Killa
This M&A ETF hits a new 52-week high. Are more gains in store for this ETF?
Bristol Myers (BMY) Gains on Positive Opdivo Data in NSCLC
by Zacks Equity Research
Bristol Myers' (BMY) shares gain as the phase III study evaluating Opdivo plus chemotherapy meets primary endpoint for the indication of NSCLC.
The Zacks Analyst Blog Highlights: Gilead, JNJ, Sanofi, BMY and MyoKardia
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Gilead, JNJ, Sanofi, BMY and MyoKardia
Biotech Stock Roundup: ALXN to Raise Guidance, BMY to Buy MYOK & Other Updates
by Zacks Equity Research
The biotech sector remains in focus with regulatory, acquisition and other pipeline updates.
Pharma M&As Pick Up as Bristol-Myers Offers to Buy MyoKardia
by Kinjel Shah
After a relatively dull first half of 2020, M&A activity in the drug and biotech sector seems to be picking up in the second half of 2020.
Healthcare ETFs Pop on Bristol Myers-MyoKardia Deal
by Sweta Killa
These funds could be the best ways for investors to tap the opportunity arising from the Bristol Myers-MyoKardia deal and will likely see smooth trading in the months to come.
Company News for Oct 6, 2020
by Zacks Equity Research
Companies in the news are: TSLA, MYOK, EIDX, GAN
Bristol Myers to Buy MyoKardia to Aid Cardiovascular Franchise
by Zacks Equity Research
Bristol Myers (BMY) offers $13.1 billion to acquire MyoKardia for diversifying its cardiovascular product portfolio. The transaction is expected to close in the fourth quarter of 2020.
Company News for May 12, 2020
by Zacks Equity Research
Companies In The News Are:
Is the Options Market Predicting a Spike in MyoKardia (MYOK) Stock?
by Zacks Equity Research
Investors need to pay close attention to MyoKardia (MYOK) stock based on the movements in the options market lately.
First-Mover Pandemic Disease Fight ETF On The Way
by Sweta Killa
Pacer Financial has filed for Pacer BioThreat ETF to enjoy the first-mover advantage that provide investors an option to capitalize on the new opportunities triggered by coronavirus.
Are Options Traders Betting on a Big Move in MyoKardia (MYOK) Stock?
by Zacks Equity Research
Investors need to pay close attention to MyoKardia (MYOK) stock based on the movements in the options market lately.
Implied Volatility Surging for MyoKardia (MYOK) Stock Options
by Zacks Equity Research
Investors need to pay close attention to MyoKardia (MYOK) stock based on the movements in the options market lately.
MyoKardia Begins Dosing in Phase I Study on Heart Candidate
by Zacks Equity Research
MyoKardia (MYOK) doses the first patient in phase I study on MYK-224, which is being evaluated for treating patients with hypertrophic cardiomyopathy, a common heart disease.
MyoKardia (MYOK) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
MyoKardia (MYOK) delivered earnings and revenue surprises of -5.06% and -100.00%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
MyoKardia (MYOK) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
MyoKardia (MYOK) delivered earnings and revenue surprises of -43.08% and -100.00%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
MyoKardia (MYOK) in Focus: Stock Moves 7.3% Higher
by Zacks Equity Research
MyoKardia (MYOK) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
Zacks.com featured highlights include: Athene, MyoKardia and Euronav
by Zacks Equity Research
Zacks.com featured highlights include: Athene, MyoKardia and Euronav
3 Earnings Acceleration Stocks You Really Need to Look At
by Tirthankar Chakraborty
Studies have shown that a majority of successful stocks had seen acceleration in earnings before an uptick in the stock price.
MyoKardia (MYOK) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
MyoKardia (MYOK) delivered earnings and revenue surprises of 22.00% and 21.45%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
MyoKardia (MYOK) Q3 Earnings Preview: What's Shaping Up?
by Zacks Equity Research
MyoKardia (MYOK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.